ArticleClinical & experimental ophthalmology2026
Long-Term Local Control and Mortality After Transpupillary Thermotherapy of Small Uveal Melanomas.
Article in Clinical & experimental ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Misdiagnosis of uveal melanoma and other intraocular malignancies in enucleated eyes: a 28-year national review.International journal of retina and vitreous · 2026Article
- Transpupillary Thermotherapy in the Treatment of Choroidal Melanomas: Does It Have a Future?Clinical & experimental ophthalmology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundTranspupillary thermotherapy (TTT) is used for selected small choroidal melanocytic tumours, either as primary treatment or as an adjunct to plaque brachytherapy. We compared long-term local recurrence and mortality outcomes after primary TTT alone, plaque brachytherapy combined with TTT (brachy+TTT), and plaque brachytherapy alone (brachy alone).
methodsThis retrospective cohort study included 850 patients with choroidal melanocytic tumours treated with eye-preserving modalities at St. Erik Eye Hospital, Stockholm, Sweden, 2008-2020. Primary treatment was TTT alone (n = 48), brachy+TTT (n = 105), or brachy alone (n = 697). Outcomes included local recurrence, local recurrence with extraocular extension (EXE), and mortality.
resultsAt 15 years, Kaplan-Meier local recurrence-free survival was 8% after TTT alone, 34% after brachy+TTT, and 86% after brachy alone (log-rank test for trend, p < 0.001). Disease-specific survival at 15 years was 46%, 85%, and 90%, respectively (p = 0.03). In multivariable Fine-Gray regression adjusting for American Joint Committee on Cancer stage, TTT alone was associated with a higher subdistribution hazard of local recurrence (sHR, 6.7; p < 0.001) and melanoma-related death (sHR, 3.9; p < 0.001). Among patients treated for local recurrence, subsequent recurrences occurred more frequently after TTT than after treatments involving brachytherapy. The risk of EXE increased with the number of TTT sessions.
conclusionsIn this single-centre retrospective cohort, TTT was associated with higher rates of local recurrence and melanoma-related mortality compared with plaque brachytherapy. Future studies should assess whether similar results are observed in external long-term cohorts; such findings would inform whether the role of TTT in the management of choroidal melanocytic tumours warrants reconsideration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.